Shire Reports Positive Phase II Results for Investigative Use of VyvanseCapsules

Shire plc (NASDAQ: SHPGY) today announced positive Phase II results in a prospective clinical study of Vyvanse® (lisdexamfetamine dimesylate) Capsules, as adjunctive therapy to primary antidepressant treatment in adults with partial or full remission of recurrent major depressive disorder (MDD) and significant, persistent cognitive impairments.

Lisdexamfetamine dimesylate is a prescription medicine currently approved in the US, Canada, and Brazil for the treatment of Attention-Deficit/Hyperactivity Disorder. Vyvanse should only be used to treat ADHD.